Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane
Epiretinal Membrane
About this trial
This is an interventional treatment trial for Epiretinal Membrane focused on measuring Epiretinal membrane, triamcinolone acetonide
Eligibility Criteria
Inclusion Criteria:
- 1.The participant must have idiopathic epiretinal membrane 2.The participant must be willing and able to comply with the protocol.
Exclusion Criteria:
1. The participant has idiopathic epiretinal membrane with other ocular vascular diseases such as Diabetes retinopathy, BRVO, etc.
2. The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy.
3. The participant has had intraocular surgery (including lens replacement surgery).
4. The participant has a history of (within the last six months), or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).
Sites / Locations
- Yeungnam University College of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Sham Comparator
Experimental
Vitrectomy only group
Combined therapy group
The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.